Literature DB >> 24786119

False-positive Papanicolaou (PAP) test rates in the College of American Pathologists PAP education and PAP proficiency test programs: evaluation of false-positive responses of high-grade squamous intraepithelial lesion or cancer to a negative reference diagnosis.

Barbara A Crothers1, Christine Noga Booth, Teresa Marie Darragh, Chengquan Zhao, Rhona J Souers, Nicole Thomas, Ann T Moriarty.   

Abstract

CONTEXT: In cytology proficiency testing (PT), participants fail for incorrectly interpreting a high-grade squamous intraepithelial lesion or cancer (HSIL+) Papanicolaou test result as negative. This penalty may lead to a false-positive interpretation of negative slides as HSIL+ to avoid failure.
OBJECTIVE: To investigate factors related to false-positive responses in a PT versus an educational environment.
DESIGN: We analyzed 420,079 responses from 9414 validated negative reference slides in the College of American Pathologists Interlaboratory Comparison Program in Gynecologic Cytopathology (PAP Education) and compared them with responses from the Gynecologic Cytology Proficiency Testing Program for the percentage of false-positive (HSIL+) interpretations in each of 7 negative subcategories. We evaluated the influence of preparation type (ThinPrep, SurePath, and conventional Papanicolaou test), participant type (pathologist or cytotechnologist), and program time interval (preproficiency test or PT) on a false-positive response.
RESULTS: Reference diagnosis and participant type, but not preparation type, were statistically correlated to false-positive responses. The interaction between program time interval and participant type was also significant. Pathologists had higher rates of false-positive results on preproficiency test (1.2% [800 of 68,690]) than they did on PT (0.8% [993 of 129,857]). Cytotechnologists had no differences between program time intervals (preproficiency, 0.9% [515 of 63,281] versus PT, 1.0 [1231 of 121,621]; P = .91). Negative subcategories frequently mistaken for HSIL+ were reparative changes (4.7% [427 of 9069]), atrophic vaginitis (1.8% [18 of 987]), and negative for intraepithelial lesion or malignancy (1.2% [2143 of 178,651]), but during PT, false-positive rates were significantly increased only for the negative for intraepithelial lesion or malignancy and herpes simplex virus (P < .001).
CONCLUSIONS: Pathologists had lower false-positive rates in the Gynecologic Cytology Proficiency Testing Program than they did in PAP Education, but participants were more likely to report a false-positive response (HSIL+) for negative for intraepithelial lesion or malignancy and herpes simplex virus in the Gynecologic Cytology Proficiency Test Program.

Entities:  

Mesh:

Year:  2014        PMID: 24786119     DOI: 10.5858/arpa.2013-0083-CP

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

1.  Study of 2 years follow-up of referral patients with abnormal Pap smear.

Authors:  Fariba Behnamfar; Azam Zafarbakhsh; Taj-Alsadat Allameh
Journal:  J Res Med Sci       Date:  2015-12       Impact factor: 1.852

2.  Endocervicoscopy and Biopsy to Detect Cervical Intraepithelial Squamous Neoplasia in Nonvisible Squamocolumnar Junction With Unsatisfactory Colposcopy: A Pilot Study.

Authors:  Siavash Rahimi; Carla Marani; Francis Gardner; Chit Cheng Yeoh; Iolia Akaev; Sergio Votano
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

3.  Pattern of cervical biopsy results in cases with cervical cytology interpreted as higher than low grade in the background with atrophic cellular changes.

Authors:  Yilan Li; Olubunmi Shoyele; Vinod B Shidham
Journal:  Cytojournal       Date:  2020-05-16       Impact factor: 2.091

4.  HPV Infection Significantly Accelerates Glycogen Metabolism in Cervical Cells with Large Nuclei: Raman Microscopic Study with Subcellular Resolution.

Authors:  Katarzyna Sitarz; Krzysztof Czamara; Joanna Bialecka; Malgorzata Klimek; Barbara Zawilinska; Slawa Szostek; Agnieszka Kaczor
Journal:  Int J Mol Sci       Date:  2020-04-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.